Matches in SemOpenAlex for { <https://semopenalex.org/work/W4288708051> ?p ?o ?g. }
- W4288708051 endingPage "3138" @default.
- W4288708051 startingPage "3119" @default.
- W4288708051 abstract "Abstract In 1999 a visionary short article by The Wall Street Journal writers Robert Langreth and Michael Waldholz popularized the new term “personalized medicine,” that is to say, the targeting of drugs to each unique genetic profile. From today’s perspective, targeted approaches have clearly found the widest use in the antineoplastic domain. The current review was initiated to review the progress that has been made regarding the treatment of patients with advanced cancer and brain metastases. PubMed was searched for the terms brain metastasis, brain metastases, or metastatic brain in the Title/Abstract. Selection was limited to randomized controlled trial (RCT) and publication date January 2010 to February 2022. Following visual review, 51 papers on metastatic lung cancer, 12 on metastatic breast cancer, and 9 on malignant melanoma were retained and underwent full analysis. Information was extracted from the papers giving specific numbers for intracranial response rate and/or overall survival. Since most pharmacological trials on advanced cancers excluded patients with brain metastases and since hardly any information on adjuvant radiotherapy and radiosurgery is available from the pharmacological trials, precise assessment of the effect of targeted medication for the subgroups with brain metastases is difficult. Some quantitative information regarding the success of targeted pharmacological therapy is only available for patients with breast and lung cancer and melanoma. Overall, targeted approaches approximately doubled the lifespan in the subgroups of brain metastases from tumors with targetable surface receptors such as anaplastic lymphoma kinase (ALK) fusion receptor in non-small cell lung cancer or human epidermal growth factor receptor 2 (HER2)–positive breast cancer. For these types, overall survival in the situation of brain metastases is now more than a year. For receptor-negative lung cancer and melanoma, introduction of immune checkpoint blockers brought a substantial advance, although overall survival for melanoma metastasized to the brain appears to remain in the range of 6 to 9 months. The outlook for small cell lung cancer metastasized to the brain apparently remains poor. The introduction of targeted therapy roughly doubled survival times of advanced cancers including those metastasized to the brain, but so far, targeted therapy does not differ essentially from chemotherapy, therefore also facing tumors developing escape mechanisms. With the improved perspective of patients suffering from brain metastases, it becomes important to further optimize treatment of this specific patient group within the framework of randomized trials." @default.
- W4288708051 created "2022-07-30" @default.
- W4288708051 creator A5024458263 @default.
- W4288708051 creator A5040312682 @default.
- W4288708051 creator A5066893984 @default.
- W4288708051 creator A5072833227 @default.
- W4288708051 date "2022-07-29" @default.
- W4288708051 modified "2023-09-30" @default.
- W4288708051 title "State of affairs regarding targeted pharmacological therapy of cancers metastasized to the brain" @default.
- W4288708051 cites W1464936406 @default.
- W4288708051 cites W1905765735 @default.
- W4288708051 cites W1917637657 @default.
- W4288708051 cites W1972132550 @default.
- W4288708051 cites W2000753370 @default.
- W4288708051 cites W2062664388 @default.
- W4288708051 cites W2066164864 @default.
- W4288708051 cites W2112121482 @default.
- W4288708051 cites W2136371443 @default.
- W4288708051 cites W2140487914 @default.
- W4288708051 cites W2146224108 @default.
- W4288708051 cites W2175378170 @default.
- W4288708051 cites W2268267848 @default.
- W4288708051 cites W2272163797 @default.
- W4288708051 cites W2324520777 @default.
- W4288708051 cites W2416907124 @default.
- W4288708051 cites W2523463218 @default.
- W4288708051 cites W2528639427 @default.
- W4288708051 cites W2564183539 @default.
- W4288708051 cites W2572174216 @default.
- W4288708051 cites W2581996620 @default.
- W4288708051 cites W2592367335 @default.
- W4288708051 cites W2594529508 @default.
- W4288708051 cites W2610816290 @default.
- W4288708051 cites W2611270905 @default.
- W4288708051 cites W2620651944 @default.
- W4288708051 cites W2623725180 @default.
- W4288708051 cites W2726861941 @default.
- W4288708051 cites W2734482945 @default.
- W4288708051 cites W2739010860 @default.
- W4288708051 cites W2752227448 @default.
- W4288708051 cites W2753432434 @default.
- W4288708051 cites W2765775340 @default.
- W4288708051 cites W2767844118 @default.
- W4288708051 cites W2790254562 @default.
- W4288708051 cites W2794627893 @default.
- W4288708051 cites W2801864212 @default.
- W4288708051 cites W2804764624 @default.
- W4288708051 cites W2887416920 @default.
- W4288708051 cites W2890523839 @default.
- W4288708051 cites W2891205725 @default.
- W4288708051 cites W2893960509 @default.
- W4288708051 cites W2894476389 @default.
- W4288708051 cites W2896375815 @default.
- W4288708051 cites W2896600825 @default.
- W4288708051 cites W2897191292 @default.
- W4288708051 cites W2897422388 @default.
- W4288708051 cites W2908888534 @default.
- W4288708051 cites W2914238967 @default.
- W4288708051 cites W2949375297 @default.
- W4288708051 cites W2977392388 @default.
- W4288708051 cites W2980868069 @default.
- W4288708051 cites W2981636558 @default.
- W4288708051 cites W2991627091 @default.
- W4288708051 cites W2997471363 @default.
- W4288708051 cites W2997513295 @default.
- W4288708051 cites W3007679475 @default.
- W4288708051 cites W3008699358 @default.
- W4288708051 cites W3009099064 @default.
- W4288708051 cites W3013118819 @default.
- W4288708051 cites W3016979687 @default.
- W4288708051 cites W3030461309 @default.
- W4288708051 cites W3033241570 @default.
- W4288708051 cites W3037795108 @default.
- W4288708051 cites W3042347895 @default.
- W4288708051 cites W3090808713 @default.
- W4288708051 cites W3101089668 @default.
- W4288708051 cites W3109853980 @default.
- W4288708051 cites W3114356388 @default.
- W4288708051 cites W3127182916 @default.
- W4288708051 cites W3137009114 @default.
- W4288708051 cites W3153241053 @default.
- W4288708051 cites W3156985612 @default.
- W4288708051 cites W3157244212 @default.
- W4288708051 cites W3162282304 @default.
- W4288708051 cites W3165169142 @default.
- W4288708051 cites W3196750844 @default.
- W4288708051 cites W3200923308 @default.
- W4288708051 cites W4200453601 @default.
- W4288708051 cites W4210837388 @default.
- W4288708051 cites W4212864919 @default.
- W4288708051 cites W4225394054 @default.
- W4288708051 cites W4225947493 @default.
- W4288708051 cites W4226051140 @default.
- W4288708051 cites W4226257711 @default.
- W4288708051 cites W4226258201 @default.
- W4288708051 cites W4226291628 @default.
- W4288708051 cites W4226406485 @default.
- W4288708051 cites W4229010465 @default.